BioXcel Therapeutics, Inc. (BTAI)
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $642.0K
- Net income
- -$69.9M
- Total assets
- $44.9M
- Market cap
- $34.1M
- Gross margin
- 74.5%
- Operating margin
- -7860.0%
- Net margin
- -10887.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $642.0K
- Cost of revenue
- $164.0K
- Gross profit
- $478.0K
- Operating expenses
- $50.9M
- Operating income
- -$50.5M
- Income tax
- $0
- Net income
- -$69.9M
- EPS (basic)
- $-5.73
- EPS (diluted)
- $-5.73
Balance sheet
- Total assets
- $44.9M
- Current assets
- $44.7M
- Total liabilities
- $140.4M
- Current liabilities
- $53.9M
- Shareholders’ equity
- -$95.5M
Cash flow
- Operating cash flow
- -$57.6M
- Investing cash flow
- $1.1M
- Financing cash flow
- $56.5M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $34.1M
- EPS (diluted)
- $-5.73
- Shares outstanding
- 40.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 8, 2018
BioXcel Therapeutics, Inc. (BTAI) Stock Price
- Reported a net loss of $69.9M in FY2025.
- Gross margin of 74.5%, net margin -10887.4%.
- Trading 88% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BioXcel Therapeutics, Inc..
Write a review
News about BioXcel Therapeutics, Inc.
News & sentiment via Polygon.io
BioXcel Therapeutics, Inc.: frequently asked questions
Is BioXcel Therapeutics, Inc. an American company?
BioXcel Therapeutics, Inc. is a US-based company headquartered in New Haven, Connecticut, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is BioXcel Therapeutics, Inc. headquartered?
BioXcel Therapeutics, Inc. is headquartered in New Haven, Connecticut, United States.
Is BioXcel Therapeutics, Inc. publicly traded?
Yes — BioXcel Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol BTAI on the NASDAQ.
What does BioXcel Therapeutics, Inc. do?
BioXcel Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
